All these data showed that CD40 mAbs play a role in stromal remodeling which transforms the immunosuppressive TME of pancreatic cancer, increases the infiltration of functional CD8+ T cells, enhances the expression of IL-2 and Th1 chemokines, and upregulates both the tumor and systemic PD-L1 expression; this could help to improve the sensitivity towards immune checkpoint therapy. Here, CD40 is linked to familial pancreatic carcinoma.